UK grants funding to Biocontrol
As part of the £4.5m, eleven project initiative, this specific project will fund a consortium of five industrial and academic partners led by Unilever. During the three year
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.